Peptides›Healing›ARA-290

ARA-290

/ 11-amino-acid peptide derived from erythropoietin; innate repair receptor (IRR) agonist

TIER 2 · TranslationalN = 0 · TESTING PENDINGLAST REVIEW 2026·04·20

ALIAS · Cibinetide

—

Pass rate

Samples

Suppliers

Research use onlyAny dose figures below describe what specific cited studies used, reported factually. Nothing on this page is guidance for human use.READ FIRST →

Terms in this page you can click for a plain-English popup: , , , , , , , .

§ A · Identity

Primary sequence— sequence not captured —

MW · —CLASS · 11-amino-acid peptide derived from erythropoietin; innate repair receptor (IRR) agonistCATEGORY · Healing

Small human Phase 2 trials in sarcoidosis-associated small fiber neuropathy (Heij 2012) reported modest improvements. Not FDA-approved. Development focus is neuropathic pain.

§ B · Mechanism of action

ARA-290 (cibinetide) is an 11-amino-acid peptide derived from the B-helix of erythropoietin. It binds the “innate repair receptor,” a complex of EPO receptor and common beta chain, without driving erythropoiesis. Proposed to modulate tissue inflammation and support small fiber nerve function.

§ C · Human clinical evidence

Small human Phase 2 trials in sarcoidosis-associated small fiber neuropathy (Heij 2012) and diabetic neuropathy have reported modest improvements in neuropathic pain and autonomic function. Not FDA-approved.

§ D · Primary literature

PubMed22714991Heij L et al. — Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study · Molecular Medicine · human-phase-2Pilot randomized trial in sarcoidosis patients with small fiber neuropathy reported improvement in neuropathic pain and autonomic function with ARA-290 (cibinetide).Limitations: Small pilot; efficacy requires confirmation in larger trials.2012

§ F · Safety signal

Published trials report generally favorable tolerability. Importantly, ARA-290 is designed to avoid EPO-receptor-mediated erythropoiesis and associated thromboembolic risk. Long-term safety data from chronic administration is limited.

§ H · Regulatory status

Regulatory status

FDA status:: Investigational (Phase 3)
Compounding:: Not eligible for compounding (approved, not in shortage)